Kotaro Kuwaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kotaro Kuwaki has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Mori
Department of Medicine, Division of Gastroenterology, School of Medicine, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan
1 shared publication - Hidenobu Ishii
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
1 shared publication - Keiichi Mitsuyama
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
1 shared publication - Osamu Tsuruta
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan
1 shared publication - Ryosuke Yamauchi
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan
1 shared publication - Shinichiro Yoshioka
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
1 shared publication
Latest Publications
- Open Access
- 31 August 2018
- Published by Springer Nature in BMC Gastroenterology
- Vol. 18 (1) , 135
The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
The use of immune-checkpoint inhibitors in cancer treatment has become increasingly common, resulting in an increase in the incidence of related side effects. Diarrhoea and colitis have been previously documented as gastrointestinal tract-related side effects of immune-checkpoint inhibitors. Although PD-1/PD-L1 inhibitors produce fewer side effects than CTLA-4 inhibitors, diarrhoea and colitis continue to be reported. However, little is known about the endoscopic features associated with PD-1/PD-L1 inhibitors. In this report, we describe three cases of colitis induced by a PD-1 inhibitor nivolumab. These cases showed endoscopic findings characteristic of ulcerative colitis (UC). Treatment was in accordance with UC therapy, which resulted in beneficial outcomes. Three patients with lung cancer treated with nivolumab presented with diarrhoea with (case 2) or without haematochezia (cases 1 and 3). Treatment with nivolumab was ceased and colonoscopy was performed, revealing endoscopic features similar to those of UC. These patients were diagnosed with nivolumab-induced colitis. Case 1 was treated with mesalazine, whereas cases 2 and 3 were treated with corticosteroids. Subsequently, their symptoms improved. Nivolumab-induced colitis exhibited similar characteristics to UC. Treatment was similar to that for UC and was successful.
- 31 August 2018
- Published by Springer Nature in BMC Gastroenterology
- Vol. 18 (1) , 135
Open AccessThe characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
The use of immune-checkpoint inhibitors in cancer treatment has become increasingly common, resulting in an increase in the incidence of related side effects. Diarrhoea and colitis have been previously documented as gastrointestinal tract-related side effects of immune-checkpoint inhibitors. Although PD-1/PD-L1 inhibitors produce fewer side effects than CTLA-4 inhibitors, diarrhoea and colitis continue to be reported. However, little is known about the endoscopic features associated with PD-1/PD-L1 inhibitors. In this report, we describe three cases of colitis induced by a PD-1 inhibitor nivolumab. These cases showed endoscopic findings characteristic of ulcerative colitis (UC). Treatment was in accordance with UC therapy, which resulted in beneficial outcomes. Three patients with lung cancer treated with nivolumab presented with diarrhoea with (case 2) or without haematochezia (cases 1 and 3). Treatment with nivolumab was ceased and colonoscopy was performed, revealing endoscopic features similar to those of UC. These patients were diagnosed with nivolumab-induced colitis. Case 1 was treated with mesalazine, whereas cases 2 and 3 were treated with corticosteroids. Subsequently, their symptoms improved. Nivolumab-induced colitis exhibited similar characteristics to UC. Treatment was similar to that for UC and was successful.